Xueming Qian - Oak Park CA, US Kevin Graham - Thousand Oaks CA, US Grant Shimamoto - Newbury Park CA, US Barbara S. Tipton - Thousand Oaks CA, US Mei-Mei Tsai - Thousand Oaks CA, US Aaron George Winters - Ventura CA, US Li Zhang - Fremont CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 39/395 C07K 16/22 C07K 16/46
US Classification:
4241581, 4241421, 4241821, 53038815, 53038824
Abstract:
The present invention relates to binding agents for WISE, and includes for their manufacture and use.
Xueming Qian - Oak Park CA, US Kevin Graham - Thousand Oaks CA, US Grant Shimamoto - Newbury Park CA, US Barbara S. Tipton - Thousand Oaks CA, US Mei-Mei Tsai - Thousand Oaks CA, US Aaron George Winters - Ventura CA, US Li Zhang - Thousand Oaks CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 39/395 C07K 16/22 C07K 16/46
US Classification:
4241581, 4241421, 4241821, 53038815, 53038824
Abstract:
The present invention relates to binding agents for WISE, and includes for their manufacture and use.
- Thousand Oaks CA, US Yi ZHANG - Dublin CA, US Jackie Z. ZHENG - Thousand Oaks CA, US Agnes Eva HAMBURGER - Newbury Park CA, US Grant SHIMAMOTO - Westlake Village CA, US Xiaoshan MIN - Burlingame CA, US Zhulun WANG - Palo Alto CA, US Jie TANG - Palo Alto CA, US Gunasekaran KANNAN - Daly City CA, US Marissa MOCK - Newbury Park CA, US Kenneth William WALKER - Newbury Park CA, US
Assignee:
AMGEN INC. - Thousand Oaks CA
International Classification:
C07K 14/475
Abstract:
Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
- Thousand Oaks CA, US Yi ZHANG - Dublin CA, US Jackie Z. SHENG - Thousand Oaks CA, US Agnes Eva HAMBURGER - Newbury Park CA, US Grant SHIMAMOTO - Westlake Village CA, US Xiaoshan MIN - Burlingame CA, US Zhulun WANG - Palo Alto CA, US Jie TANG - Palo Alto CA, US Gunasekaran KANNAN - Daly City CA, US Kenneth W. WALKER - Newbury Park CA, US Bryan LEMON - Mountain View CA, US
GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
- Thousand Oaks CA, US Yi ZHANG - Dublin CA, US Jackie Z. SHENG - Thousand Oaks CA, US Agnes Eva HAMBURGER - Newbury Park CA, US Grant SHIMAMOTO - Westlake Village CA, US Xiaoshan MIN - Burlingame CA, US Zhulun WANG - Palo Alto CA, US Jie TANG - Palo Alto CA, US Gunasekaran KANNAN - Daly City CA, US Marissa MOCK - Newbury Park CA, US Kenneth William WALKER - Newbury Park CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
C07K 14/475
Abstract:
Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
- Thousand Oaks CA, US Yi ZHANG - Dublin CA, US Jackie Z. SHENG - Thousand Oaks CA, US Agnes Eva HAMBURGER - Newbury Park CA, US Grant SHIMAMOTO - Westlake Village CA, US Xiaoshan MIN - Burlingame CA, US Zhulun WANG - Palo Alto CA, US Jie TANG - Palo Alto CA, US Gunasekaran KANNAN - Daly City CA, US Kenneth W. WALKER - Newbury Park CA, US Bryan LEMON - Mountain View CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
C07K 14/475 A61K 39/00
Abstract:
GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
- Thousand Oaks CA, US Yi ZHANG - Dublin CA, US Jackie Z. SHENG - Thousand Oaks CA, US Agnes Eva HAMBURGER - Newbury Park CA, US Grant SHIMAMOTO - Westlake Village CA, US Xiaoshan MIN - Burlingame CA, US Zhulun WANG - Palo Alto CA, US Jie TANG - Palo Alto CA, US Gunasekaran KANNAN - Daly City CA, US Marissa MOCK - Newbury Park CA, US Kenneth WALKER - Newbury Park CA, US
International Classification:
C07K 14/475
Abstract:
Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
- San Francisco CA, US Yi Zhang - Dublin CA, US Jackie Zeqi Sheng - Thousand Oaks CA, US Agnes Eva Hamburger - Newbury Park CA, US Grant Shimamoto - Westlake Village CA, US Xiaoshan Min - Burlingame CA, US Zhulun Wang - Palo Alto CA, US Jie Tang - Palo Alto CA, US Gunasekaran Kannan - Newbury Park CA, US Kenneth W. Walker - Newbury Park CA, US Bryan Lemon - Mountain View CA, US
International Classification:
C07K 14/475
US Classification:
5303873
Abstract:
GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
Resumes
Co Founder And Vice President Research And Development
Amgen Aug 1991 - Oct 2013
Principal Scientist
Bio-Spring Aug 1991 - Oct 2013
Co Founder and Vice President Research and Development
Education:
Wayne State University
Doctorates, Doctor of Philosophy, Microbiology, Immunology
Yale University
California Polytechnic State University - San Luis Obispo
Bachelors, Bachelor of Science, Biochemistry, Organic Chemistry
Wayne State University School of Medicine
Doctorates, Microbiology, Immunology
Yale University School of Medicine
Doctorates
Michigan State University
Master of Science, Masters, Biochemistry
Skills:
Drug Discovery Biotechnology Protein Chemistry Lifesciences Antibodies Biopharmaceuticals Assay Development Drug Development Cell Culture Molecular Biology Monoclonal Antibodies Protein Purification Technology Transfer Cell Biochemistry Chromatography Clinical Development Elisa Glp Gmp Hplc Immunology In Vitro Life Sciences Oncology Pharmaceutical Industry Purification Sds Page High Performance Liquid Chromatography